Nanologica has recruited Ulf Ericsson as VP Drug Development as part of the strategy to enhance focus on the respiratory field and inhalation, within the business area Drug Development. Mr. Ericsson will be responsible for leading the work on developing inhalable pharmaceuticals.
To accelerate the development of the NLAB Spiro® inhalation platform, Ulf Ericsson has been recruited as VP Drug Development. The position includes leading efforts and strategy for the development and commercialization of the platform.
” We believe the potential of the NLAB Spiro® platform to be huge, though we are still in early stages. Having Mr. Ericsson join our team and take the lead on developing and commercializing the platform is a great stride towards our goal – to provide new treatments for patients with severe lung disease – and his vast experience will truly strengthen our inhouse competency within the field. We are very excited to welcome him to Nanologica and his joining is another step in building a stellar team for taking the company to new heights”, says Andreas Bhagwani, CEO of Nanologica.
Ulf Ericsson has more than 20 years’ global experience in the inhaled respiratory therapeutic area, whereof 17 years at AstraZeneca. Most recently, he held the position as Global Sr Director Respiratory Inhalation, where he was leading the global inhaled device strategy work for AstraZeneca’s inhaled portfolio and was commercially responsible for all inhaler devices and formulations across AstraZeneca’s commercialized portfolio, as well as leading the commercial part for development of future inhalation devices, formulations, and platforms.
Mr. Ericsson also has an extensive experience in insight-driven brand strategy development and implementation, as well as in forecasting, evaluation, and business case development. His appointment is effective as of September 1st.
For further information, please contact:
Johanna Johansson, IR Nanologica
Ph: +46 72 211 21 90 or e-mail: email@example.com
About Nanologica AB (publ)
Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface characteristics of silica particles. Through the two business areas, Drug Development and Chromatography, we strive towards reducing healthcare disparities throughout the world for the betterment of mankind. In Drug Development, we are committed to leverage our technology platform to solve medical problems in order to provide new treatments for patients with severe lung diseases. In Chromatography, we aim to make insulin available to more patients in need by reducing the production cost for manufacturers. Nanologica operates from the headquarters in Södertälje, Sweden and Nanologica’s stock (NICA) is listed on Spotlight Stock Market. For further information, please visit www.nanologica.com.